Activation of DR3 Signaling Causes Loss of ILC3s and Exacerbates Intestinal Inflammation

Jingyu Li,Wenli Shi,Hanxiao Sun,Yan Ji,Yuqin Chen,Xiaohuan Guo,Huiming Sheng,Jie Shu,Liang Zhou,Ting Cai,Ju Qiu

DOI: https://doi.org/10.1038/s41467-019-11304-8

IF: 16.6

2019-01-01

Nature Communications

Abstract:TNF-like ligand 1 A (TL1A) and death receptor 3 (DR3) are a ligand-receptor pair involved in the pathogenesis of inflammatory bowel disease. Group 3 innate lymphoid cells (ILC3s) regulate intestinal immunity and highly express DR3. Here, we report that activation of DR3 signaling by an agonistic anti-DR3 antibody increases GM-CSF production from ILC3s through the p38 MAPK pathway. GM-CSF causes accumulation of eosinophils, neutrophils and CD11b + CD11c + myeloid cells, resulting in loss of ILC3s from the intestine in an IL-23-dependent manner and exacerbating colitis. Blockade of GM-CSF or IL-23 reverses anti-DR3 antibody-driven ILC3 loss, whereas overexpression of IL-23 induces loss of ILC3s in the absence of GM-CSF. Neutralization of TL1A by soluble DR3 ameliorates both DSS and anti-CD40 antibody-induced colitis. Moreover, ILC3s are required for the deleterious effect of anti-DR3 antibodies on innate colitis. These findings clarify the process and consequences of DR3 signaling-induced intestinal inflammation through regulation of ILC3s.